文献速递淋巴瘤

CARiBOU方案一线治疗套细胞淋巴瘤的多中心2期试验结果

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
PubMed 文献 · Am J Hematol · 2026-06-17

CARiBOU(ACCRU-LY-1804)是一项多中心2期试验,评估VR-CAP与R-阿糖胞苷交替联合持续阿可替尼一线治疗初治套细胞淋巴瘤。41例可评估患者中39例(95%)缓解,37例(90%)达完全代谢缓解,18个月PFS为79%(95%CI 64%-97%),OS为96%(95%CI 88%-100%)。

要点

  • 初治MCL中CARiBOU方案CMR率达90%,总体缓解率95%。
  • 18个月PFS 79%(95%CI 64%-97%),OS 96%(95%CI 88%-100%)。
  • 主要毒性为血液学,3级血液学AE 78%,无治疗相关死亡。

核心结论

  • CARiBOU是高效、可行的门诊一线MCL方案,采用中剂量阿糖胞苷和持续阿可替尼6周期。
  • 该多靶点方案应对MCL生物学异质性,并支持基于MRD指导的巩固和维持决策。

研究设计与样本

  • 多中心2期试验(ACCRU-LY-1804/CARiBOU,NCT04626791),纳入初治MCL患者。
  • 方案为VR-CAP与R-阿糖胞苷交替联合持续阿可替尼,共6个21天周期。
  • 主要终点为完全代谢缓解(CMR)率,次要终点包括安全性、干细胞采集可行性、ASCT比例、PFS和OS。
  • 入组41例,采用ClonoSEQ检测外周血MRD。

主要发现

  • 39例(95%)缓解,37例(90%)达CMR;2例非缓解者因毒性早期停药。
  • 33例可测MRD中26例(79%)在10^-6阈值未检出,94%在10^-5阈值未检出。
  • 18个月估计PFS 79%(95%CI 64%-97%),OS 96%(95%CI 88%-100%)。
  • 发热性中性粒细胞减少4例,SAE 6例(14%),无治疗相关死亡。

关键数值与推荐

  • CMR率90%(37/41),总体缓解率95%(39/41)。
  • MRD未检出率:10^-6阈值79%(26/33),10^-5阈值94%。
  • 18个月PFS 79%(95%CI 64%-97%),OS 96%(95%CI 88%-100%)。
  • 3级血液学AE 78%(32/41),SAE 14%(6/41)。

临床怎么用

  • CARiBOU可作为初治MCL的门诊多靶点一线选择,尤其适合需要灵活MRD指导后续治疗者。
  • 治疗中需重点监测血液学毒性,必要时血小板输注支持。
  • MRD检测可辅助判断巩固和维持策略。

局限性

  • 2期单臂设计,样本量41例,随访时间有限。
  • MRD检测仅33例可评估,非全部入组患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary endpoints included safety, feasibility of stem cell collection, proportion proceeding to ASCT, and progression-free (PFS) and overall survival (OS). Peripheral blood measurable residual disease (MRD) was tested using the ClonoSEQ assay (Adaptive Biotechnologies). Of 41 patients enrolled, 39 (95%) responded to therapy, including 37 patients achieving CMR (90%). Two nonresponders discontinued therapy for toxicity early, prior to study-defined restaging, and received alternate therapy. Undetectable MRD at a 106 threshold was achieved in 26/33 tested patients (79%), and 94% at 105. 18-month estimated PFS is 79% (95% CI 64%-97%), and OS is 96% (95% CI 88%-100%). Toxicities were primarily hematologic (grade 3 hematologic AE in 32 patients, [78%]). Twelve required platelet transfusions, and one grade 3 bleeding event occurred. Febrile neutropenia occurred in 4 patients, and 6 (14%) experienced SAEs. There were no treatment-related deaths. CARiBOU is an efficient, highly effective outpatient 1st line MCL regimen, employing intermediate-dose cytarabine and continuous acalabrutinib for 6 cycles. This multitargeted regimen addresses the biologic heterogeneity of MCL and permits flexible MRD-guided decisions on consolidation and maintenance. Trial Registration: ClinicalTrials.gov identifier: NCT04626791.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Smith SD, Sundaram S, Giri S, et al. Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. Am J Hematol. 2026. PMID: 42305039. doi:10.1002/ajh.70406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。